Agenda

Attendees listening to debates

Agenda

January 30 - February 1, 2026

Register

January 30 - February 1, 2026

- Room
  - Talbot ABC
- 8:40 AM – 9:00 AM
  
  Newly diagnosed AML: Does the Newest Data Support 7+3?
- 9:00 AM – 9:20 AM
  
  Updates in Targeted Triplet Induction Regimens in AML for 2026 Practice
- 9:20 AM – 9:40 AM
  
  Evolving Clinical Applications: The Expanding Role of MRD in AML
- 9:40 AM – 10:00 AM
  
  Who Should Be Transplanted in AML? Evolving Criteria and New Evidence
- 10:00 AM – 10:15 AM
  
  Question & Answer Panel
- Room
  - Talbot FH
Sold to AbbVie
- Room
  - Talbot ABC
- 11:20 AM – 11:40 AM
  
  Myelodysplastic Syndromes (MDS): New Data and Evolving Treatment Paradigms
- 11:40 AM – 12:00 PM
  
  Updates in Myeloproliferative Neoplasms: Translating Emerging Evidence into Practice
- 12:00 PM – 12:20 PM
  
  Evolving Management of ALL: Integrating 2025 Data into 2026 Practice
- 12:20 PM – 12:35 PM
  
  Question & Answer Panel
- 12:35 PM – 1:20 PM
  
  Real Cases, Real Decisions: Turning Evidence Into Expertise
- Room
  - Talbot FH
Sold to Lilly
- Room
  - Talbot ABC
- 2:55 PM – 3:15 PM
  
  Updates in Upfront Diffuse Large B-cell Lymphoma (DLBCL) Informed by 2025 Data
- 3:15 PM – 3:35 PM
  
  New Therapy Options in Relapsed Refractory DLBCL
- 3:35 PM – 3:55 PM
  
  Current Approaches in Mantle Cell Lymphoma
- 3:55 PM – 4:10 PM
  
  Question & Answer Panel
- 4:10 PM – 4:55 PM
  
  Real Cases, Real Decisions: Turning Evidence Into Expertise
- Room
  - Talbot FH
Pending

- Room
  - Talbot ABC
- 8:40 AM – 9:00 AM
  
  Waldenström’s Macroglobulinemia Management: What’s New and What’s Next
- 9:00 AM – 9:20 AM
  
  The Latest Updates in Follicular Lymphoma
- 9:20 AM – 9:40 AM
  
  Marginal Zone Lymphoma: Advancing Toward 2026 with New Clinical Insights
- 9:40 AM – 10:00 AM
  
  My Evolving Approach to Hodgkin Lymphoma: Lessons from 2025 Data
- 10:00 AM – 10:15 AM
  
  Question & Answer Panel
- Room
  - Talbot ABC
- 10:45 AM – 11:05 AM
  
  Updates in BTKi + BCL2i Combinations
- 11:05 AM – 11:25 AM
  
  Updates in Management of BTKi Resistance and Mutations
- 11:25 AM – 11:45 AM
  
  Continuous versus Fixed Duration Therapy - Lessons from 2025 Data
- 11:45 AM – 12:05 PM
  
  BTK Degraders: Emerging Clinical Data and What Lies Ahead
- 12:05 PM – 12:20 PM
  
  Question & Answer Panel
- Room
  - Talbot FH
Sold to AbbVie
- Room
  - Talbot ABC
- 1:25 PM – 1:45 PM
  
  Richter Transformation - What is New?
- 1:45 PM – 2:05 PM
  
  Bispecifics versus CAR T Cell - The Roadmap for 2026
- 2:05 PM – 2:25 PM
  
  The Next Frontier: What’s Left to Learn After the Latest Global Update
- 2:25 PM – 2:40 PM
  
  Question & Answer Panel
- 2:40 PM – 3:25 PM
  
  Real Cases, Real Decisions: Turning Evidence Into Expertise
- Room
  - Talbot FH
Sold to GSK

- Room
  - Talbot ABC
- 8:05 AM – 8:25 AM
  
  What’s new in Front Line Treatment for Transplant Eligible Patients -Auto or CART?
- 8:25 AM – 8:45 AM
  
  The Future of Frontline Treatment for Transplant-Ineligible Patients: Bispecifics vs. CAR T
- 8:45 AM – 8:55 AM
  
  Question & Answer Panel
- Room
  - Talbot FH
Sold to Regeneron
- Room
  - Talbot ABC
- 10:00 AM – 10:20 AM
  
  From 2025 Discoveries to 2026 Practice: Evolving Strategies in Early Relapsed Myeloma
- 10:20 AM – 10:40 AM
  
  Beyond the Triple-Class Barrier: Emerging Strategies and Real-World Insights in Relapsed Myeloma
- 10:40 AM – 11:00 AM
  
  New Molecules in Refractory Myeloma (CelMoDs & iMIDS) - Updates from 2025
- 11:00 AM – 11:15 AM
  
  Question & Answer Panel
- 11:15 AM – 12:00 PM
  
  Real Cases, Real Decisions: Turning Evidence Into Expertise
- Room
  - Talbot FH
Sold to JnJ
- Room
  - Talbot ABC
- 1:05 PM – 1:25 PM
  
  Who Will We Treat in 2026? High-Risk Smoldering Limited vs Full-Quad Treatment
- 1:25 PM – 1:45 PM
  
  Gaps in Care: Extramedular, CNS Disease, and Plasma Cell Leukemia
- 1:45 PM – 1:55 PM
  
  Question & Answer Panel